PHATHOM PHARMACEUTICAL

9,0900

25-ноября-24 16:45:01

15 мин. задержка

Акции

-0,2500

-2,68%

Сегодняшний диапазон

8,7600 - 9,5691

ISIN

N/A

Источник

NASDAQ

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

28 фев 2023 08:00:03 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals Provides Regulatory Updates

09 фев 2023 16:01:00 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

08 янв 2023 18:00:00 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis

03 янв 2023 16:01:00 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates

08 ноя 2022 17:00:00 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences

03 ноя 2022 08:30:00 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement

01 ноя 2022 08:00:02 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)

24 окт 2022 08:00:02 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

23 окт 2022 12:01:00 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

18 окт 2022 08:00:02 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

26 сен 2022 08:00:00 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

07 сен 2022 08:15:00 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates

02 авг 2022 11:48:42 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

01 июн 2022 08:15:00 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis

25 май 2022 08:00:01 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022

24 май 2022 12:15:00 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting

17 май 2022 08:01:00 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates

10 май 2022 08:00:01 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital

04 май 2022 08:01:00 Источник Nasdaq GlobeNewswire
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

03 май 2022 17:40:31 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.